Lexaria Debt Ratio from 2010 to 2025

LEXXW Stock

USD 0.25 0.05 25.00%

Lexaria Bioscience Debt Ratio yearly trend continues to be fairly stable with very little volatility. Debt Ratio will likely drop to 0.20 in 2025. During the period from 2010 to 2025, Lexaria Bioscience Debt Ratio regression line of quarterly data had mean square error of 0.01 and geometric mean of 0.04. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.35741259

Current Value

0.2

Quarterly Volatility

0.08877793

Credit Downgrade

Yuan Drop

Covid

Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 129 K, Interest Expense of 125.2 K or Other Operating Expenses of 7.5 M, as well as many indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.

Check out the analysis of Lexaria Bioscience Correlation against competitors.

Latest Lexaria Bioscience's Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of Lexaria Bioscience Corp over the last few years. It is Lexaria Bioscience's Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexaria Bioscience's overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

Lexaria Debt Ratio Regression Statistics

	Arithmetic Mean	0.08
	Geometric Mean	0.04
	Coefficient Of Variation	114.11
	Mean Deviation	0.05
	Median	0.08
	Standard Deviation	0.09
	Sample Variance	0.01
	Range	0.3542
	R-Value	0.30
	Mean Square Error	0.01
	R-Squared	0.09
	Significance	0.26
	Slope	0.01
	Total Sum of Squares	0.12

Lexaria Debt Ratio History

	2025	0.2
	2024	0.36
	2023	0.0155
	2022	0.0532
	2021	0.006381
	2020	0.007336

Other Fundumenentals of Lexaria Bioscience Corp

Cash Flow To Debt Ratio

Lexaria Bioscience Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Net Receivables	Short Term Debt	Intangible Assets	Long Term Debt	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Capital Stock	Short Long Term Debt
Total Assets		0.99	-0.89	-0.71	0.64	0.28	0.96	-0.58	-0.45	0.44	-0.23	0.78	-0.6	0.66	0.72	0.91	0.89	0.66	-0.82	-0.52
Total Stockholder Equity	0.99		-0.94	-0.73	0.59	0.15	0.99	-0.55	-0.51	0.43	-0.31	0.79	-0.64	0.7	0.73	0.93	0.91	0.72	-0.84	-0.49
Net Debt	-0.89	-0.94		0.7	-0.46	0.12	-0.97	0.41	0.52	-0.35	0.43	-0.72	0.67	-0.7	-0.68	-0.93	-0.92	-0.77	0.79	0.33
Retained Earnings	-0.71	-0.73	0.7		-0.69	-0.09	-0.75	0.34	0.44	-0.38	0.6	-0.97	0.82	-0.9	-0.9	-0.59	-0.51	-0.32	0.84	0.45
Accounts Payable	0.64	0.59	-0.46	-0.69		0.42	0.62	-0.45	0.11	0.0	-0.24	0.74	-0.43	0.45	0.57	0.44	0.39	-0.1	-0.59	-0.79
Total Liab	0.28	0.15	0.12	-0.09	0.42		0.05	-0.43	0.16	0.17	0.4	0.12	0.15	-0.02	0.05	0.12	0.1	-0.18	-0.12	-0.15
Total Current Assets	0.96	0.99	-0.97	-0.75	0.62	0.05		-0.49	-0.46	0.38	-0.39	0.8	-0.67	0.7	0.73	0.92	0.9	0.68	-0.84	-0.52
Common Stock	-0.58	-0.55	0.41	0.34	-0.45	-0.43	-0.49		0.55	0.14	-0.28	-0.42	-0.07	-0.14	-0.27	-0.59	-0.58	-0.38	0.74	0.3
Current Deferred Revenue	-0.45	-0.51	0.52	0.44	0.11	0.16	-0.46	0.55		-0.25	0.18	-0.43	0.3	-0.45	-0.43	-0.56	-0.54	-0.77	0.73	-0.12
Net Receivables	0.44	0.43	-0.35	-0.38	0.0	0.17	0.38	0.14	-0.25		-0.2	0.39	-0.52	0.6	0.52	0.34	0.31	0.47	-0.22	-0.01
Short Term Debt	-0.23	-0.31	0.43	0.6	-0.24	0.4	-0.39	-0.28	0.18	-0.2		-0.47	0.6	-0.53	-0.47	-0.26	-0.22	-0.2	0.33	0.18
Intangible Assets	0.78	0.79	-0.72	-0.97	0.74	0.12	0.8	-0.42	-0.43	0.39	-0.47		-0.79	0.88	0.94	0.63	0.56	0.34	-0.86	-0.59
Long Term Debt	-0.6	-0.64	0.67	0.82	-0.43	0.15	-0.67	-0.07	0.3	-0.52	0.6	-0.79		-0.9	-0.78	-0.46	-0.4	-0.33	0.57	0.32
Capital Surpluse	0.66	0.7	-0.7	-0.9	0.45	-0.02	0.7	-0.14	-0.45	0.6	-0.53	0.88	-0.9		0.91	0.6	0.53	0.45	-0.69	-0.23
Property Plant Equipment	0.72	0.73	-0.68	-0.9	0.57	0.05	0.73	-0.27	-0.43	0.52	-0.47	0.94	-0.78	0.91		0.59	0.51	0.42	-0.73	-0.45
Net Invested Capital	0.91	0.93	-0.93	-0.59	0.44	0.12	0.92	-0.59	-0.56	0.34	-0.26	0.63	-0.46	0.6	0.59		0.99	0.8	-0.79	-0.26
Net Working Capital	0.89	0.91	-0.92	-0.51	0.39	0.1	0.9	-0.58	-0.54	0.31	-0.22	0.56	-0.4	0.53	0.51	0.99		0.82	-0.75	-0.23
Short Term Investments	0.66	0.72	-0.77	-0.32	-0.1	-0.18	0.68	-0.38	-0.77	0.47	-0.2	0.34	-0.33	0.45	0.42	0.8	0.82		-0.59	0.07
Capital Stock	-0.82	-0.84	0.79	0.84	-0.59	-0.12	-0.84	0.74	0.73	-0.22	0.33	-0.86	0.57	-0.69	-0.73	-0.79	-0.75	-0.59		0.42
Short Long Term Debt	-0.52	-0.49	0.33	0.45	-0.79	-0.15	-0.52	0.3	-0.12	-0.01	0.18	-0.59	0.32	-0.23	-0.45	-0.26	-0.23	0.07	0.42

Click cells to compare fundamentals

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's Debt Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Debt Ratio	0.36	0.20
Cash Flow To Debt Ratio	0.25	0.26

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexaria Debt Ratio from 2010 to 2025

Latest Lexaria Bioscience's Debt Ratio Growth Pattern

Lexaria Debt Ratio Regression Statistics

Lexaria Debt Ratio History

Other Fundumenentals of Lexaria Bioscience Corp

Lexaria Bioscience Debt Ratio component correlations

About Lexaria Bioscience Financial Statements

Also Currently Popular

Additional Tools for Lexaria Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY